Axogen, Inc. (NASDAQ: AXGN) reported an insider transaction on March 16, 2026, when Chief Innovation Officer Erick Wayne DeVinney sold 5,221 shares of common stock at $32.84 per share, generating approximately $171,457 in proceeds.
The Form 4 filing with the Securities and Exchange Commission shows a related disposal that same day: DeVinney sold 2,870 shares at the identical $32.84 price, a transaction valued at $94,250. That sale was executed to satisfy tax obligations tied to the vesting of restricted stock units.
Also recorded on March 16, 2026, were option exercises by DeVinney to acquire two lots of Axogen common stock - one for 6,363 shares and another for 11,575 shares - with the restricted stock units vesting on that date. The filings indicate the exercises and vesting coincided with the share sales documented on the Form 4.
The insider activity occurred against a backdrop of substantial share appreciation earlier in the past year. Axogen’s stock had climbed roughly 86% over the previous 12 months and was up about 90% over the prior six months, though the price had retreated to $30.94 following those gains.
Analysts tracking the company continue to express a bullish stance, citing price targets in a range from $39 to $43 per share. Separately, Axogen’s fourth-quarter 2025 financial results exceeded consensus expectations: adjusted earnings per share came in at $0.07 versus a $0.06 estimate, and revenue was reported at $59.9 million compared with Street expectations of $58.25 million.
The quarterly revenue outcome represents a 21.3% year-over-year increase and matched the company’s preannouncement from January, arriving roughly 3% above the Street projection referenced at that time. Even with the upside in earnings and revenue, Axogen’s stock showed a decline in pre-market trading following the release.
In the realm of analyst coverage, Citizens reiterated a Market Outperform rating on Axogen and maintained a price target of $42.00.
These filings and quarterly results provide a snapshot of an executive liquidity event tied to equity compensation mechanics - option exercises and RSU vesting - combined with market reactions to recent financial performance.